Last reviewed · How we verify
Antihyperglycemic agent(s)
Antihyperglycemic agents work by reducing blood glucose levels through various mechanisms such as enhancing insulin secretion, improving insulin sensitivity, or reducing hepatic glucose production.
Antihyperglycemic agents work by reducing blood glucose levels through various mechanisms such as enhancing insulin secretion, improving insulin sensitivity, or reducing hepatic glucose production. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Antihyperglycemic agent(s) |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Diabetes |
| Phase | Phase 3 |
Mechanism of action
This is a broad drug class category rather than a single agent. Antihyperglycemic agents encompass multiple drug classes (e.g., metformin, sulfonylureas, GLP-1 agonists, SGLT2 inhibitors, DPP-4 inhibitors) that lower blood glucose through distinct mechanisms. Without specification of the exact agent or mechanism from Janssen's Phase 3 program, the precise molecular target and mechanism cannot be determined.
Approved indications
- Type 2 diabetes mellitus
Common side effects
Key clinical trials
- iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) (PHASE3)
- The REmission of Diabetes Using a PlAnt-based Weight Loss InteRvention (REPAIR) Trial (NA)
- Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea (PHASE2)
- Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin (PHASE3)
- Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s) (PHASE3)
- Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy (PHASE3)
- Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s) (PHASE3)
- A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |